Search

Background: Since the discovery of SARS-CoV-2, no treatment has been able to completely eradicate the virus. The study aimed to evaluate the virological and clinical impact of the vaccination in SARS-CoV-2 infected patients treated with monoclonal antibodies (mAbs)., Methods: This single-centre, observational, retrospective, real-life study was performed on SARS-CoV-2 symptomatic outpatients and inpatients treated with mAbs from March 2021 to November 2022 includes 726 patients. Each patient received available mAbs (bamlanivimab-etesevimab or casirivimab-indevimab or sotrovimab or tixagevimab-cilgavimab) according to the circulating virus strains. Age, comorbidities, vaccination status, death rates, duration of virological clearance, average length of stay, risk factors, and hospitalization or ICU admission were recorded., Results: Of 726 patients with complete data analyzed (median age 64), 516 outpatients and 210 inpatients were included. Vaccination status was known for all participants: 74.4 % and 51.7 % were vaccinated against SARS-CoV-2 among inpatients and outpatients, respectively. A shorter duration of virological clearance was observed in the vaccinated group, with a median of 16 days (IQR 15-17), compared to 19 days (IQR 18-21) in the unvaccinated group [HR 1.21; p < 0.032]. Multivariate analysis of virological clearance also showed statistical significance with tixagevimab cilgavimab 300 mg/300 mg (HR 2.73, p value < 0.001). No significant difference was found in worsening [OR 1,29; p = 0.57] and mortality [OR 0.65; p = 0.81] rates between vaccinated and unvaccinated patients treated with mAbs., Conclusions: Key findings include a shorter duration of virological clearance in vaccinated outpatients but no significant differences in worsening or mortality rates between vaccinated and unvaccinated patients treated with mAbs. The study suggests a potential synergistic role of mAbs in accelerating virological clearance in vaccinated patients with mild to moderate COVID-19, with differing effects in hospitalized patients. Therefore, it is essential to implement health surveillance in high-risk patients with comorbidities in order to identify early any variants that might otherwise escape neutralizing antibodies., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)

Background: Anterior cruciate ligament injuries are among the most common injuries in high impact sports, and reconstruction is the standard surgical procedure for these ruptures. Reconstructions are often performed using allografts rather than autografts on a case-by-case basis. Controversy exists as to whether or not age of donor tissue plays a factor in the mechanical properties of allografts., Methods: 38 peroneus longus (PL) tendons were prepared using the two-strand graft technique and then subjected to a cyclic loading test regimen of 1000 cycles to determine material properties. Specimens were grouped based on age to ascertain whether donor age affects the material properties of PL tendons., Findings: Secant modulus of the first cycle was determined to be 150.43 (SD 40.24) MPa. The average magnitude of the dynamic modulus was determined to be 82.81 (SD 24.65) MPa. Specimens were grouped into three distinct groups for analysis (x < 40 yo, 40 yo ≤ x < 60 yo, 60 yo < x)., Interpretation: The need for using intrinsic material properties is highlighted. There is no significant difference in any intrinsic material property with respect to age or the fatigue of the tendon as the cycle count increases. Conversely, the measured stiffness of a tendon decreased as function of age with a large effect size. Based on analysis of graft geometries, it was determined that PL tendons become significantly more slender with increased age which result in the observed decrease in stiffness., (Copyright © 2019 Elsevier Ltd. All rights reserved.)